T2 Biosystems to Highlight its Products and Technology at Upcoming Medical Meetings
June 12 2019 - 7:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development
of innovative diagnostic products for critical unmet needs in
healthcare, announced today that it will highlight its rapid
molecular diagnostic products and technology, including the
T2Bacteria® and T2Candida® Panels, at three medical meetings in
June 2019: Biodefense World Summit 2019, ASM Microbe 2019, and APIC
2019.
The Biodefense World Summit 2019 will take place on June 17-19,
2019 in Bethesda, MD. At the meeting, Tom Lowery, chief scientific
officer of T2 Biosystems, will make a presentation titled “A Rapid,
Direct-from-Blood Diagnostic to Address Infections from Multidrug
Resistance Organisms (MDROs)” at 12:00 pm ET on Monday, June 17,
2019. Dr. Lowery’s presentation will highlight how the clinical use
of the Company’s T2MR® technology, which enables the rapid
detection of sepsis-causing bacterial and fungal pathogens directly
from whole blood without the wait for blood culture, is advancing
patient care and addressing the multidrug resistant organisms
(MDRO) public health threat, such as the recently emerging
superbug, Candida auris. Dr. Lowery will also highlight potential
future uses of the T2MR technology for biodefense applications.
ASM Microbe 2019, a major annual meeting of the American Society
for Microbiology, will take place on June 20-24, 2019 in San
Francisco, CA. At the meeting, the Company will host an Industry
and Science Showcase event at 12:00 pm PT on Friday, June 21, 2019
that will describe the Company’s T2MR technology, highlight the
latest T2Bacteria Panel clinical data, review successful
implementation strategies for hospitals, and discuss patient case
studies from recent customer use and as it relates to supporting
antimicrobial stewardship challenges, and further the discussion on
how the Company is addressing the multidrug resistant organisms
(MDRO) public health threat, such as Candida auris. The event will
also highlight potential future advancements of the T2MR technology
in the field of sepsis management. Additionally, the Company will
also exhibit the T2Bacteria and T2Candida Panels with in-booth
presentations (booth 1443) throughout the meeting, which will be
attended by clinical lab professionals, clinicians, and
researchers.
APIC 2019, the annual meeting of the Association for
Professionals in Infection Control and Epidemiology, will take
place on June 12-14, 2019 in Philadelphia, PA. The Company will
showcase its products at booth 130 during the meeting, which will
be attended by healthcare professionals involved in infection
prevention.
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel and are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease.
Media Contact: Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024